Protocol Ledger

NCT05712694 · Phase III · TERMINATED

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Interventional Phase III clinical trial protocol NCT05712694 sponsored by Polaris Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-29 Enrollment: 218 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05712694
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)218 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05712694
Protocol FieldVerified Registry Value
NCT IdentifierNCT05712694
Consolidated Lead SponsorPolaris Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment218 participants (ACTUAL)
Registered Start Date2023-11-29
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI